Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
CA-125 response as a marker of clinical benefit in...
Conference

CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib-A trial of the PMH Phase II Consortium

Authors

Welch S; Hirte H; Elit L; Schilder RJ; Pond G; Kovacs J; Wright J; Oza AM

Volume

25

Publisher

AMER SOC CLINICAL ONCOLOGY

Publication Date

June 20, 2007

Conference proceedings

JOURNAL OF CLINICAL ONCOLOGY

Issue

18

ISSN

0732-183X

Labels

Fields of Research (FoR)